

Update to Criteria – Allowed Length of Treatment for Mavyret

On September 26, 2019, the FDA approved a treatment duration of 8 weeks of Mavyret for patients with compensated cirrhosis who are treatment-naive. The purpose of this memo is to inform you that Maryland Medicaid has determined that all Mavyret approvals for patients with compensated cirrhosis shall only be approved for a duration of 8 weeks. Moreover, this change will take effect on November 1, 2019. Any new HCV therapy of Mavyret on or after the effective date will be approved for only two fills. For any treatment starting on or after November 1, 2019, any requests for more than 8 weeks of treatment will need to include the rationale for the length of treatment in order to be reviewed as a possible exception to the criteria from Maryland Medicaid.